Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Peking University People's Hospital8 sites in 1 country116 target enrollmentApril 2003

ConditionsAdvanced MDS Without Identical Sibling Donor

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Advanced MDS Without Identical Sibling Donor
Sponsor: Peking University People's Hospital
Enrollment: 116
Locations: 8
Primary Endpoint: survival rate
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS), especially for advanced MDS (blast >5%). However, many patients cannot find an HLA-matched donor. haploidentical donor is an alternative stem cell source.

the study hypothesis: Haploidentical/mismatched hematopoietic stem cell transplantation can improve the survival of patients with myelodysplastic syndrome

Registry

clinicaltrials.gov

Start Date

April 2003

End Date

December 2014

Last Updated

11 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Peking University People's Hospital

Responsible Party

Principal Investigator

Xiaojun Huang

Prof.

Peking University People's Hospital

Eligibility Criteria

Inclusion Criteria

•Patients with MDS (1)intermediate-2 or high risk (2)low or intermediate-1 risk with drug resistance or disease progression
•without identical sibling donor